Oztan et al. identified the EGFR G724S variant in two T790M‐positive NSCLC patients whose disease progressed while on osimertinib treatment, suggesting that G724S is another potential acquired mutation leading to resistance to third‐generation EGFR‐TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.